ALG-170675

November 6, 2026: Aligos Therapeutics (NASDAQ: ALGS) reported pipeline and financial updates focused on chronic hepatitis B. Pevifoscorvir sodium, a small-molecule CAM-E, continues in the Phase 2 B-SUPREME study (NCT06963710); enrollment is complete with 131 participants in the HBeAg+ cohort (Part 1a) and 114 in the HBeAg- cohort (Part 2a), and topline data for both cohorts are expected in late Q3 2027. The company also said 70 participants have completed 48 weeks of treatment.

ALG-170675, an antisense oligonucleotide for chronic HBV, has been advanced by partner Amoytop into Phase 1 clinical studies in China. Amoytop is funding development in China and holds Greater China rights; Aligos said it may use data from these studies for regulatory filings and other purposes under the parties’ agreement.

Financially, cash, cash equivalents, and investments were $31.1 million as of September 30, 2026, versus $77.8 million at December 31, 2025, and the company expects this to fund planned operations into Q1 2027. Q3 2026 net loss was $21.9 million, compared with $31.5 million in Q3 2025.